|  | OF HEALTH AND HUMAN SERV<br>AND DRUG ADMINISTRATION   | /ICES   |  |
|--|---|---|--|
| DISTRICT ADDRESS AND PHONE NUMBER  |   | OF INSPECTION   |  |
| 4040 North Central Expressway, Suit  | e 300 9/17.   | /2018-11/19/2018*   |  |
| Dallas, TX 75204   |   | 087152  |  |
| (214)253-5200 Fax: (214)253-5314   | 200   | 007132  |  |
| NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED   |   |   |  |
| Ms. Ashley M. Downing, Co-Owner  |   |   |  |
| FIRM NAME  | STREET ADDRESS  |   |  |
| Downing Labs, LLC  | 4001 McEwen Rd Ste 110  |   |  |
| CITY, STATE, ZIP CODE, COUNTRY   | TYPE ESTABLISHMENT INSPECTED  |   |  |
| Dallas, TX 75244-5020  | Producer of Sterile Drugs   |   |  |
| This document lists observations made by the FDA represe<br>observations, and do not represent a final Agency determin<br>observation, or have implemented, or plan to implement, co<br>action with the FDA representative(s) during the inspection<br>questions, please contact FDA at the phone number and ad- | ation regarding your compliance.<br>orrective action in response to an or submit this information to FD | . If you have an objection regarding an observation, you may discuss the objection or |  |

# OBSERVATION 1

Equipment was not disinfected prior to entering the aseptic processing areas.

Specifically, your firm's pharmacy I.V. support staff and pharmacy technician failed to disinfect:

- beaker containing (b) (4) liquid EDTA Disodium drug product.
- 2. A pair of scissors utilized to open packages in the ISO 5 environment.
- in the ISO 5 environment. utilized to (b) (4)

These pieces of equipment were utilized during the production of EDTA Disodium 150mg/ml, 50 ml volume, Batch #'s S10242018@13 and S10242018@14, Manufacture Date 10/25/2018.

## **OBSERVATION 2**

The ISO 5 classified aseptic processing areas had difficult to clean equipment or surface.

Specifically, your ISO 5 processing suite has a (b) (4) installed partially in the ISO 5 area where the cabinet of the equipment has air vents that are not easily cleaned and disinfected. Also, there is a fan unit inside the (b) (4) which creates a risk of spreading particles in the ISO 5 environment.

| ott T Ballard, Investigator<br>son R Caballero, Investigator | Scott 1 Bulland<br>Investigator<br>Sprind by Scott 1 Berland -5<br>Date Sugment 11-78-2018 10-561 1 | 11/19/2018   |
|--|---|--|
|  |   | son R Caballero, Investigator Scott Bullary Investigator |

|  | ALTH AND HUMAN SERVICES<br>RUG ADMINISTRATION |
|--|---|
| DISTRICT ADDRESS AND PHONE NUMBER                    | DATE(S) OF INSPECTION                         |
| 4040 North Central Expressway, Suite 300             | 0 9/17/2018-11/19/2018*                       |
| Dallas, TX 75204<br>(214)253-5200 Fax: (214)253-5314 | 3010087152                                    |
| NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED   |   |
| Ms. Ashley M. Downing, Co-Owner                      |   |
| FIRM NAME  | STREET ADDRESS                                |
| Downing Labs, LLC                                    | 4001 McEwen Rd Ste 110                        |
| CITY, STATE, ZIP CODE, COUNTRY                       | TYPE ESTABLISHMENT INSPECTED                  |
| Dallac TV 75244-5020                                 | Producer of Sterile Drugs                     |

There are no environmental monitoring samples collected from the (b) (4) cabinet and most difficult-to-clean portions of this equipment.

#### OBSERVATION 3

Results of stability testing are not used in determining appropriate storage conditions.

Specifically, your firm is assigning Beyond Use Dates (BUDs) to sterile human drug products for a time period that extends past failing test data for potency and particulates.

| Product Name                                | Lot#          | Date<br>Compounded | Labeled<br>BUD | Qty<br>Distributed | Concern   |
|---|---------------|--------------------|----------------|--------------------|---|
| TNPDR Buffered and Preserved for injection  | S01172018/a/2 | 17-Jan-18          | 22-Feb-18      | (b) (4)            | >6000 count particulates at 30 days                           |
| Folic Acid 10mg/mL - 30 ml, for injection   | S12142017@1   | 27-Dec-17          | 16-Feb-18      |                    | 53% sub-potent at 35 days                                     |
| L-Glutathione 200mg/mL - 50mL for injection | \$12132017@2  | 14-Dec-17          | 2-Mar-18       | -                  | 50% sub-potent at 65 days                                     |
| Dexpanthenol 250mg/ml. 30ml. for injection  | S12112017@1   | 11-Dec-17          | 26-Feb-18      |                    | BUD 15 days beyond passing results, 80% sub-potent at 92 days |

## **OBSERVATION 4**

Your facility was designed and/or operated in a way that permits poor flow of materials.

Specifically, your pharmacy technician failed to clear equipment wrappers and used wipes out of the ISO 5 environment during the production of EDTA Disodium 150mg/ml, 50 ml volume, Batch #'s \$10242018@13 and \$10242018@14, Manufacture Date 10/25/2018. These sterile equipment wrappers and sterile wipes were used and stayed present in the ISO 5 environment throughout production.

## \*DATES OF INSPECTION

| SEE REVERSE<br>OF THIS PAGE | EMPLOYEE(S)SIGNATURE  Scott T Ballard, Inve Jason R Caballero, Ir | -                        | Scoti T Baltand<br>Investigator<br>Signed By, Scoti T, Baltand -S<br>Date Signed, 11-19-2018 to 58-11 | DATE ISSUED 11/19/2018 |
|-----------------------------|---|--------------------------|---|------------------------|
| FORM FDA 483 (09/08)        | PREVIOUS EDITION OBSOLETE   | INSPECTIONAL OBSERVATION | ONS   | PAGE 2 of 3 PAGES      |

|  | DEPARTMENT OF HEAL  | TH AND HUMAN                 | SERVIC   | FS  |                           |
|--|---|------------------------------|--|---|---------------------------|
| DISTRICT ADDRESS AND PHO   | FOOD AND DRUG   | ADMINISTRATION               | V  |   |                           |
|  | Central Expressway, Suite 300   |                              | DATE(S) OF INSPECTION<br>9/17/2018-11/19/2018* |   | *                         |
| Dallas, TX 7   |   |                              | FEI NUMBER                                     |   |                           |
|  | 0 Fax: (214)253-5314  | 1                            | 301008   | 7152  |                           |
| NAME AND TITLE OF INDIVIDU   | AL TO WHOM REPORT ISSUED  |                              |  |   |                           |
| TABLE OF THE PARTY | . Downing, Co-Owner   |                              |  |   |                           |
| FIRM NAME STREET ADDRES  |   |                              | ESS  |   |                           |
| Downing Labs   | s, LLC 4001 McE   |                              | Ewen Rd Ste 110                                |   |                           |
| CITY, STATE, ZIP CODE, COUN  |   | TYPE ESTABLISHMENT INSPECTED |  |   |                           |
| Dallas, TX 7   | 5244-5020   | Producer of Sterile Drugs    |  |   |                           |
| 9/28/2018(Fri),  | a), 9/18/2018(Tue), 9/19/2018(Wed), 10/16/2018(Tue), 10/22/2018(Mon), 10/30/2018(Tue), 11/01/2018(The | , 10/23/2018                 | (Tue),   | 10/24/2018(Wed)   | ,                         |
| SEE REVERSE<br>OF THIS PAGE  | EMPLOYEE(S) SIGNATURE Scott T Ballard, Investigato Jason R Caballero, Investiga                       |                              |  | Scott T Batterd<br>in Scott T Batterd Scott T Batterd S<br>Scott T Batterd S<br>Date Signed 11-19-2018 10-56-11 | DATE ISSUED<br>11/19/2018 |